Gossamer Bio (GOSS) Tax Provisions (2024 - 2025)
Gossamer Bio (GOSS) posted quarterly Tax Provisions of -$88000.0 for Q4 2025, up 96.35% year-over-year from -$44818.3 in Q4 2024, and up 96.35% quarter-over-quarter from -$2.4 million in Q4 2024.
Gossamer Bio (GOSS) Tax Provisions (2024 - 2025) Analysis & Trends
Gossamer Bio's Tax Provisions history runs 2 years deep, the most recent figure standing at -$88000.0 for Q4 2025.
- In Q4 2025, Tax Provisions rose 96.35% year-over-year to -$88000.0; the TTM figure through Dec 2025 stood at -$2.5 million (down 380.67% YoY), while the FY2025 annual figure was -$88000.0, down 109.85% from the prior year.
- Tax Provisions for Q4 2025 stood at -$88000.0, up from -$2.4 million in the prior quarter.
- The five-year high for Tax Provisions was $4.4 million in Q2 2024, with the low at -$2.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -88,000.00 |
| Dec 31, 2024 | -2.41 Mn |
| Sep 30, 2024 | -1.10 Mn |
| Jun 30, 2024 | 4.40 Mn |